Drugs Made In America Acquisition (NASDAQ:DMAA) Issues Quarterly Earnings Results

Drugs Made In America Acquisition (NASDAQ:DMAA) released its quarterly earnings data on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, FiscalAI reports.

Drugs Made In America Acquisition Trading Down 0.1%

Shares of NASDAQ:DMAA traded down $0.01 on Friday, reaching $10.58. The company had a trading volume of 211 shares, compared to its average volume of 87,862. The firm’s 50 day simple moving average is $10.52 and its 200-day simple moving average is $10.43. Drugs Made In America Acquisition has a 52-week low of $10.10 and a 52-week high of $10.60.

Hedge Funds Weigh In On Drugs Made In America Acquisition

A number of institutional investors have recently modified their holdings of DMAA. Quarry LP purchased a new stake in shares of Drugs Made In America Acquisition in the third quarter valued at approximately $161,000. Sandia Investment Management LP purchased a new stake in shares of Drugs Made In America Acquisition during the 3rd quarter valued at approximately $161,000. Radcliffe Capital Management L.P. lifted its stake in shares of Drugs Made In America Acquisition by 3.5% in the 4th quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock valued at $5,673,000 after purchasing an additional 18,708 shares during the last quarter. Lineage Point Capital LP acquired a new position in Drugs Made In America Acquisition during the fourth quarter worth $330,000. Finally, Shaolin Capital Management LLC raised its stake in shares of Drugs Made In America Acquisition by 50.0% in the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company’s stock valued at $1,540,000 after acquiring an additional 50,000 shares in the last quarter.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank?check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.